tbuckley/cabot-search huggingface dataset:
Reply to: Correspondence on Editorial regarding “Genetically modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Authors: Antonio Bertoletti, Anthony T Tan
Journal: Clinical and Molecular Hepatology (2024)

Reply to: Correspondence on Editorial regarding "Genetically modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting"
New Recessive Dystrophic Epidermolysis Bullosa intermediate variant resulting from alternative splicing of exon 19 and truncation in FN III-like domain of type VII collagen
Authors: Aleksandra A Martynova, Alexey A Kubanov, Nadezhda A Evtushenko, Anastasiya V Kosykh, Nikolay V Kondratyev, Arkadii K Beilin, Arfenya E Karamova, Ekaterina S Monchakovskaya, Ekaterina A Bogdanova, Karim A Azimov, Rustam H Ziganshin, Maria A Nefedova, Nina G Bozhanova, Elena V Zaklyazminskaya, Nadya G Gurskaya
Journal: British Journal of Dermatology (2024)

Here we described two unrelated cases of a new pathogenic variant in COL7A1, the deletion c.2588-3_2588delCAGC. The variant causes alternative splicing in the preceding exon and results in truncation of fibronectin III (FN-III) like domain of C7. This new variant is distinct from previously documented variants as it does not completely exclude exon 19, restores open reading frame of COL7A1 and results in a less severe form of RDEB intermediate.
Pediatric Cranial Stereotactic Radiosurgery: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines
Authors: Erin S Murphy, Arjun Sahgal, Jean Regis, Marc Levivier, Laura Fariselli, Alessandra Gorgulho, Lijun Ma, Bruce Pollock, Shoji Yomo, Jason Sheehan, Ian Paddick, John H Suh, Anshul Saxena, Md Ashfaq Ahmed, Rupesh Kotecha
Journal: Neuro-Oncology (2024)

Abstract Background There are limited data on the use of stereotactic radiosurgery (SRS) for pediatric patients. The aim of this systematic review was to summarize indications and outcomes specific to pediatric cranial SRS to inform consensus guidelines on behalf of the International Stereotactic Radiosurgery Society. Methods A systematic review, using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses, analyzed English-language articles on SRS, published between 1989 and 2021, that included outcomes for at least 5 pediatric patients. MEDLINE database terms included tumor types and locations, and radiosurgical and age-specific terms. We excluded nonclinical reports, expert opinions, commentaries, and review articles. Meta-regressions for associations with local control were performed for medulloblastoma, craniopharyngioma, ependymoma, glioma, and arteriovenous malformation (AVM). Results Of the 113 articles identified for review, 68 met the inclusion criteria. These articles described approximately 400 pediatric patients with benign and malignant brain tumors and 5119 with AVMs who underwent cranial SRS. The rates of local control for benign tumors, malignant tumors, and AVMs were 89% (95% CI, 82%–95%), 71% (95% CI, 59%–82%), and 65% (95% CI, 60%–69%), respectively. No significant associations were identified for local control with the patient-, tumor-, or treatment-related variables. Conclusions This review is the first to summarize outcomes specific to SRS for pediatric brain tumors and AVMs. Although data reporting is limited for pediatric patients, SRS appears to provide acceptable rates of local control. We present ISRS consensus guidelines to inform the judicious use of cranial SRS for pediatric patients.
Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges
Authors: Yan Zhang, Xinyu Shi, Yifan Shen, Xiulin Dong, Ruiqing He, Guo Chen, Yan Zhang, Honghong Tan, Kun Zhang
Journal: MedComm (2024)

Abstract Oncolytic viruses (OVs) have emerged as a powerful tool in cancer therapy. Characterized with the unique abilities to selectively target and lyse tumor cells, OVs can expedite the induction of cell death, thereby facilitating effective tumor eradication. Nanoengineering‐derived OVs overcome traditional OV therapy limitations by enhancing the stability of viral circulation, and tumor targeting, promising improved clinical safety and efficacy and so on. This review provides a comprehensive analysis of the multifaceted mechanisms through which engineered OVs can suppress tumor progression. It initiates with a concise delineation on the fundamental attributes of existing OVs, followed by the exploration of their mechanisms of the antitumor response. Amid rapid advancements in nanomedicine, this review presents an extensive overview of the latest developments in the synergy between nanomaterials, nanotechnologies, and OVs, highlighting the unique characteristics and properties of the nanomaterials employed and their potential to spur innovation in novel virus design. Additionally, it delves into the current challenges in this emerging field and proposes strategies to overcome these obstacles, aiming to spur innovation in the design and application of next‐generation OVs.
Poliomyelitis in Gaza
Authors: Nitin Gupta, Martin P. Grobusch, Pikka Jokelainen, Anne L. Wyllie, Aleksandra Barac, Marta Mora-Rillo, Effrossyni Gkrania-Klotsas, Galadriel Pellejero-Sagastizabal, José Ramón Paño-Pardo, Erwin Duizer, François-Xavier Lescure
Journal: Clinical Microbiology and Infection (2024)
Double Enzyme Active Hydrogel Program Regulates the Microenvironment of <i>Staphylococcus aureus</i>‐Infected Pressure Ulcers
Authors: Hailin Xie, Yuna Qian, Jiayi Ding, Rui Zhao, Linwei Huang, Jianliang Shen, Zhihua Zhou
Journal: Advanced Healthcare Materials (2024)

Abstract The treatment of infected pressure ulcers (IUPs) requires addressing diverse microenvironments. A pressing challenge is to effectively enhance the regenerative microenvironment at different stages of the healing process, tailoring interventions as needed. Here, a dual enzyme mimetic and bacterial responsive self‐activating antimicrobial hydrogel designed to enhance IPUs healing is introduced. This hydrogel incorporates pH‐responsive dual enzyme‐active nanoplatforms (HNTs‐Fe‐Ag) encapsulated within a methacrylate‐modified silk fibroin (SFMA) and dopamine methacrylamide (DMA) matrix. This composite hydrogel exhibits adaptive microenvironment regulation capabilities. Under the low pH microenvironment of bacterial infection, it has excellent antimicrobial activity by self‐activating the •OH generation in conjunction with photothermal effects. Under the neutral and alkaline microenvironment of chronic inflammation, it catalyzes the decomposition of hydrogen peroxide (H 2 O 2 ) to produce oxygen (O 2 ), thereby alleviating hypoxia and scavenging reactive oxygen species (ROS), which in turn remodulates the phenotype of macrophages. The composite hydrogel demonstrates on‐demand therapeutic effects in the microenvironment of infected wounds, significantly enhancing the regenerative microenvironment of IUPs by promoting wound closure, inflammation regulation, and collagen deposition through self‐activated antimicrobial action during infection and adaptive hypoxia relief during recovery. This approach offers a novel strategy for developing smart wound dressings.
Structure‐based design of antibodies targeting the EBNA1 DNA‐binding domain to block Epstein–Barr virus latent infection and tumor growth
Authors: Yongyue Han, Fang Wu, Ying Zhang, Jun Liu, Yuzhe Wu, Yuecheng Wang, Xiwen Jiang, Xin Chen, Wei Xu
Journal: MedComm (2024)

Abstract The Epstein–Barr virus (EBV) nuclear antigen 1 (EBNA1) is critically involved in maintaining episomes during latent infection and promoting tumorigenesis. The development of an epitope‐specific monoclonal antibody (mAb) for EBNA1 holds great promise due to its high affinity and specificity, offering a new and innovative approach for the treatment of EBV‐related diseases. In this proof‐of‐concept study, we employed a structure‐based design strategy to create three unique immunogens specifically targeting the DNA binding state of the EBNA1 DBD. By immunizing mice, we successfully generated a mAb, named 5E2‐12, which selectively targets the DNA binding interface of EBNA1. The 5E2‐12 mAb effectively disrupts the interaction between EBNA1 and DNA binding, resulting in reduced proliferation of EBV‐positive cells and inhibition of xenograft tumor growth in both cellular assays and mouse tumor models. These findings open up new avenues for the development of innovative biological macromolecular drugs that specifically target EBNA1 and provide potential for clinical therapy options for early‐stage EBV‐positive tumors. The epitope‐specific mAb approach demonstrates novelty and innovation in tackling EBV‐related diseases and may have broad implications for precision medicine strategies in the field of viral‐associated cancers.
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Authors: Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi, Nicholas D James, Neal Shore, Eric Small, Matthew Smith, Christopher J Sweeney, Bertrand Tombal, Thomas Zilli, Neeraj Agarwal, Emmanuel S Antonarakis, Ana Aparicio, Andrew J Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna Ayadi, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Maria T Bourlon, Alberto Briganti, Muhammad Bulbul, Consuelo Buttigliero, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H Cheng, Kim N Chi, Caroline S Clarke, Noel Clarke, Johann S de Bono, Maria De Santis, Ignacio Duran, Eleni Efstathiou, Onyeanunam N Ekeke, Tamer I H El Nahas, Louise Emmett, Stefano Fanti, Omolara A Fatiregun, Felix Y Feng, Peter C C Fong, Valerie Fonteyne, Nicola Fossati, Daniel J George, Martin E Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Michael S Hofman, Thomas A Hope, Lisa G Horvath, Maha H A Hussain, Barbara Alicja Jereczek-Fossa, Robert J Jones, Anthony M Joshua, Ravindren Kanesvaran, Daniel Keizman, Raja B Khauli, Gero Kramer, Stacy Loeb, Brandon A Mahal, Fernando C Maluf, Joaquin Mateo, David Matheson, Mika P Matikainen, Ray McDermott, Rana R McKay, Niven Mehra, Axel S Merseburger, Alicia K Morgans, Michael J Morris, Hind Mrabti, Deborah Mukherji, Declan G Murphy, Vedang Murthy, Shingai B A Mutambirwa, Paul L Nguyen, William K Oh, Piet Ost, Joe M O'Sullivan, Anwar R Padhani, Chris Parker, Darren M C Poon, Colin C Pritchard, Danny M Rabah, Dana Rathkopf, Robert E Reiter, Raphaele Renard-Penna, Charles J Ryan, Fred Saad, Juan Pablo Sade, Shahneen Sandhu, Oliver A Sartor, Edward Schaeffer, Howard I Scher, Nima Sharifi, Iwona A Skoneczna, Howard R Soule, Daniel E Spratt, Sandy Srinivas, Cora N Sternberg, Hiroyoshi Suzuki, Mary-Ellen Taplin, Camilla Thellenberg-Karlsson, Derya Tilki, Levent N Türkeri, Hiroji Uemura, Yüksel Ürün, Claire L Vale, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y Yu, Almudena Zapatero, Aurelius Omlin
Journal: European Urology (2024)

Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024.
GDF-15 improves the predictive capacity of Steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies
Authors: Michail Kokkorakis, Pytrik Folkertsma, José Castela Forte, Bruce H R Wolffenbuttel, Sipko van Dam, Christos S Mantzoros
Journal: Metabolism (2024)
Mesenchymal stem cell-loaded hydrogel to inhibit inflammatory reaction in surgical brain injury via mitochondria transfer
Authors: Yunzhi Wang, Xin Yang, Menghui Liu, Yang Yan, Fangen Kong, Jikai Wang, Zichen Zhang, Yanlv Chen, Lei Chen, Zibin Liang, Xin Peng, Fei Liu
Journal: Journal of Controlled Release (2024)
Controlled dual drug release from adhesive electrospun patches for prevention and treatment of alveolar osteitis
Authors: Klaudia M Slowik, Jake G Edmans, Samuel Harrison, Sean M Edwards, Robert Bolt, Sebastian G Spain, Paul V Hatton, Craig Murdoch, Helen E Colley
Journal: Journal of Controlled Release (2024)

Approximately one in five individuals experience alveolar osteitis (AO) following wisdom tooth extraction. AO is characterised by loss of the blood clot from the tooth extraction socket leading to infection and pain, resulting in repeated hospital visits that impose a substantial burden on healthcare systems. Current treatments are sub-optimal; to address this we developed a novel drug-loaded mucoadhesive patch composed of dual electrospun polyvinyl pyrrolidone/Eudragit RS100 (PVP/RS100) and poly(N-isopropylacrylamide) (PNIPAM) fibres protected by a poly(ε-caprolactone) (PCL) backing layer. These patches demonstrated controlled release of the long-acting analgesic bupivacaine HCl and the anti-inflammatory drug prednisolone. Topical application of patches to tissue-engineered gingival mucosa showed that patch-released bupivacaine and prednisolone achieved sustained tissue permeation with 54.8 ± 3.3 % bupivacaine HCl and 65.8 ± 5.1 % prednisolone permeating the epithelium after 24 h. The drugs retained their functionality after release; bupivacaine HCl significantly (p < 0.05) inhibited veratridine-induced intracellular calcium flux in SH-SY5Y neuronal cells, while prednisolone significantly reduced gene expression of IL-6 (2-fold; p < 0.001), CXCL8 (5.1-fold; p < 0.01) and TNF-α (1.5-fold; p < 0.001) in stimulated THP-1 monocytes. Taken together, these data show that dual electrospun patches have the potential to provide a mucoadhesive covering to prevent blood clot loss while delivering pain relief and anti-inflammatory therapeutics at tooth extraction sites to prevent and treat AO. This study not only offers a future therapeutic pathway for AO but also contributes valuable insights into future advancements in drug delivery devices for periodontal or oral mucosal tissue.
Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma
Authors: Matthew Gallitto, Xu Zhang, Genesis De Los Santos, Hong-Jian Wei, Ester Calvo Fernández, Shoufu Duan, Geoffrey Sedor, Nina Yoh, Danae Kokossis, J Carlos Angel, Yi-Fang Wang, Erin White, Connor J Kinslow, Xander Berg, Lorenzo Tomassoni, Fereshteh Zandkarimi, Iok In Christine Chio, Peter Canoll, Jeffrey N Bruce, Neil A Feldstein, Robyn D Gartrell, Simon K Cheng, James H Garvin, Stergios Zacharoulis, Robert J Wechsler-Reya, Jovana Pavisic, Andrea Califano, Zhiguo Zhang, Cheng-Chia Wu
Journal: Neuro-Oncology (2024)

Abstract Background Diffuse midline glioma (DMG) is the most aggressive primary brain tumor in children. All previous studies examining the role of systemic agents have failed to demonstrate a survival benefit; the only standard of care is radiation therapy (RT). Successful implementation of radiosensitization strategies in DMG remains an essential and promising avenue of investigation. We explore the use of Napabucasin, an NAD(P)H quinone dehydrogenase 1 (NQO1)-bioactivatable reactive oxygen species (ROS)-inducer, as a potential therapeutic radiosensitizer in DMG. Methods In this study, we conduct in vitro and in vivo assays using patient-derived DMG cultures to elucidate the mechanism of action of Napabucasin and its radiosensitizing properties. As penetration of systemic therapy through the blood-brain barrier (BBB) is a significant limitation to the success of DMG therapies, we explore focused ultrasound (FUS) and convection-enhanced delivery (CED) to overcome the BBB and maximize therapeutic efficacy. Results Napabucasin is a potent ROS-inducer and radiosensitizer in DMG, and treatment-mediated ROS production and cytotoxicity are dependent on NQO1. In subcutaneous xenograft models, combination therapy with RT improves local control. After optimizing targeted drug delivery using CED in an orthotopic mouse model, we establish the novel feasibility and survival benefit of CED of Napabucasin concurrent with RT. Conclusions As nearly all DMG patients will receive RT as part of their treatment course, our validation of the efficacy of radiosensitizing therapy using CED to prolong survival in DMG opens the door for exciting novel studies of alternative radiosensitization strategies in this devastating disease while overcoming limitations of the BBB.
Transient ST-segment elevation myocardial infarction without flow-limiting obstructions in the epicardial coronary arteries on angiography: coronary artery vasospasm, myocardial infarction with non-obstructive coronary arteries or spontaneous coronary artery dissection?
Authors: Sahrai Saeed, Trond Cooper, Anne Margrethe Tveit, Svein Rotevatn, Terje H Larsen
Journal:  (2024)
Autoimmune CD4+ T cells fine-tune TCF1 expression to maintain function and survive persistent antigen exposure during diabetes
Authors: Nouf Aljobaily, Denise Allard, Bryant Perkins, Arielle Raugh, Tessa Galland, Yi Jing, W Zac Stephens, Matthew L Bettini, J Scott Hale, Maria Bettini
Journal: Immunity (2024)
Day-to-day associations between pain intensity and sleep outcomes in an adult chronic musculoskeletal pain population: A systematic review
Authors: Z Goossens, A Van Stallen, J Vermuyten, M De Deyne, D Rice, N Runge, E Huysmans, T Vantilborgh, J Nijs, O Mairesse, L De Baets
Journal: Sleep Medicine Reviews (2024)
Immuno-persistence after the 4th and 5th dose of inactivated polio vaccines in school-aged children
Authors: Kathy Leung, Chrissy W.K. Pang, Tiffany H.K. Lo, Juan C. Vargas-Zambrano, Céline Petit, Tommy T.Y. Lam, Eric H.Y. Lau, Joseph T. Wu
Journal: Clinical Microbiology and Infection (2024)

ObjectiveThis study aimed to assess the long-term persistence of neutralising antibodies (nAb) titres and seroprotection proportions after the 4th and 5th doses of inactivated polio vaccine (IPV).MethodsSerum samples from 299 children in Hong Kong were collected and used to estimate the persistence of nAb titres and seroprotection proportions by neutralisation test.ResultsThe mean nAb titres against polioviruses type 1, 2 and 3 (PV1, PV2 and PV3) one month after receiving the 4th dose of IPV at 19 months of age were 2,068 (95% credible interval: 1,517 – 2,864), 4,705 (3,439 – 6,436) and 2,758 (1,894 – 4,086), but declined substantially in 4 years to 268 (222 – 325), 751 (630 – 900), and 411 (323 – 521), respectively. Administration of the 5th dose of IPV restored nAb titres among children aged 6-7 years, and the decline in nAb titres was slightly slower with the estimated mean titres of 355 (272 – 462), 538 (427 – 681), and 548 (378 – 786) against PV1, PV2, and PV3 at 4 years post the 5th dose. We estimated that the proportion of children who were seroprotected against PV1, PV2 and PV3 would drop below 90% at: (i) 8.2, 10.8, 8.7 years after the 4th dose; and (ii) 11.6, 11.2, 11.0 years after the 5th dose.ConclusionsThe results revealed the immuno-persistence after the 4th and 5th dose of IPV and highlighted the importance of completing immunization series to ensure high vaccination coverage, particularly among children in the developing countries affected by the COVID-19 pandemic.
Clinical characteristics and genetic analysis of 14 patients affected with acne fulminans and hidradenitis suppurativa: ASH syndrome, a new phenotypic entity
Authors: Snaigune Miskinyte, Sabine Duchatelet, Maïa Delage, Marie-Noëlle Ungeheuer, Nicole Auffret, Raphaëlle Binois, Philippe Guillem, Olivier Join-Lambert, Aude Nassif, Alain Hovnanian
Journal: Journal of the American Academy of Dermatology (2024)
Exploring Suicidal and Self-injurious Behaviors (SSIBs) Signal Strength of Biologics in Treating Psoriasis or Psoriatic Arthritis: A 10-year Real-world Pharmacovigilance Analysis Using FAERS Database
Authors: Yu-Fan Cheng, Ming Chen, Xiong-Yu Li, Cai-Lan Hou, Zhu Shen
Journal: Journal of the American Academy of Dermatology (2024)
Recommended Guidelines for Screening for Underlying Malignancy in Extramammary Paget's Disease Based on Anatomic Subtype
Authors: Nour Kibbi, Joshua L. Owen, Brandon Worley, Murad Alam, Jake X. Wang, Vishnu Harikumar, Malia B. Downing, Sumaira Z. Aasi, Phyu P. Aung, Christopher A. Barker, Diana Bolotin, Jeremy S. Bordeaux, Todd V. Cartee, Sunandana Chandra, Nancy L. Cho, Jennifer N. Choi, Kee Yang Chung, William A. Cliby, Oliver Dorigo, Daniel B. Eisen, Yasuhiro Fujisawa, Nicholas Golda, Thorvardur R. Halfdanarson, Christos Iavazzo, Shang I. Brian Jiang, Esther M. John, Jean Kanitakis, Emily L. Keimig, Ashraf Khan, Eleni Linos, John Y.S. Kim, Timothy M. Kuzel, Naomi Lawrence, Mario M. Leitao, Allan B. MacLean, Ian A. Maher, Bharat B. Mittal, Kishwer S. Nehal, David M. Ozog, Curtis A. Pettaway, Neil Rajan, Jeffrey S. Ross, Anthony M. Rossi, Sabah Servaes, Michael J. Solomon, Valencia D. Thomas, Maria Tolia, Bryan B. Voelzke, Abigail Waldman, Michael K. Wong, Youwen Zhou, Alexandria Brackett, Emily Poon, Areeba Ahmed
Journal: Journal of the American Academy of Dermatology (2024)
Favorable prognosis of subcutaneous sarcoidosis: French cohort of 80 patients compared with dermal sarcoidosis
Authors: Jeanne Chauffier, François Chasset, Maxime Battistella, Marie Jachiet, Marie-Dominique Vignon Pennamen, Elisabeth Cohen, Nicolas Dupin, Coralie Lheure, Edouard Begon, Didier Bessis, Adèle de Masson, Vincent Jachiet, Jeremy Gottlieb, Alexandre Teboul, Blanche Bergeret, Emilie Brenaut, Sebastien Debarbieux, Pierre Gazengel, Abdellatif Tazi, Hilario Nunes, Jean-David Bouaziz, Thibault Mahévas
Journal: Journal of the American Academy of Dermatology (2024)
Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation
Authors: Xin Kong, Ziyi Xu, Yanjun Wu, Xiaowen Tang, Shengli Xue, Miao Miao, Yue Han, Ying Wang, Suning Chen, Aining Sun, Huiying Qiu, Depei Wu, Ye Zhao, Feng Chen
Journal: Journal of Hematology & Oncology (2024)

Letermovir (LTV) prophylaxis is effective in reducing the incidence of clinically significant cytomegalovirus (CMV) infection (cs CMVi) after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Since our centre began administering LTV prophylaxis in June 2022, we have observed a certain increase in the incidence of Epstein–Barr virus (EBV) reactivation after haploidentical HSCT. We retrospectively analysed 230 consecutive patients who underwent haploidentical HSCT with rabbit anti-thymocyte globulin (ATG) from October 2022 to June 2023. The LTV group included 133 patients who received LTV prophylaxis, and the control group included 97 patients who did not receive LTV prophylaxis. At 1 year after HSCT, EBV reactivation was observed in 36 patients (27%) in the LTV group and 13 patients (13%) in the control group (p = 0.012). All patients with EBV reactivation had EBV-DNAemia, and one patient in each group developed EBV-associated posttransplantation lymphoproliferative disorder (PTLD). The proportion of patients with low EBV-DNA loads (> 5 × 102 to < 1 × 104 copies/mL) was greater in the LTV group than in the control group (23% vs. 10%, p = 0.01). The proportion of patients with CMV reactivation was lower in the LTV group than in the control group (35% vs. 56%, p = 0.002). There was no significant difference between the groups in terms of neutrophil and platelet count recovery, the cumulative incidence of acute/chronic graft-versus-host disease, overall survival, cumulative relapse rate or nonrelapse mortality. Our results show that the increased incidence of EBV reactivation may be associated with LTV prophylaxis for CMV after haploidentical HSCT.